SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

H

Huihua Xiong

Status and phase

Not yet enrolling
Phase 2

Conditions

Breasr Cancer

Treatments

Drug: Bevacizumab
Drug: SHR-A1811

Study type

Interventional

Funder types

Other

Identifiers

NCT06361979
A1811

Details and patient eligibility

About

This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases

Enrollment

30 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ≥18 years old;
  • Pathologically confirmed HER2-positive breast cancer;
  • At least one measurable intracranial lesion according to RANO-BM criteria, which had not received local treatment;
  • More than 2 weeks from last systemic treatment; patients with new brain lesions after craniocerebral surgery were admitted if no radiotherapy was performed.
  • Prior HER2-target treatment, endocrine therapy and chemotherapy was allowed;
  • Adequate function of major organs-

Exclusion criteria

  • Previous treatment with trastuzumab deruxtecan (DS-8201a) or any other antibody drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase 1 inhibitor;
  • Previous treatment with bevacizumab;
  • Participated in other drug clinical trials within 4 weeks before admission;
  • History of clinically significant lung disease;
  • Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.
  • According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.).

Any other conditions that researchers believe that patients are unsuitable for this study.

-

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

ARM1
Experimental group
Treatment:
Drug: SHR-A1811
Drug: Bevacizumab

Trial contacts and locations

0

Loading...

Central trial contact

Xiong huihua

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems